A low AMH result is one of the most frightening numbers a woman can be handed, but it is often misunderstood. AMH estimates how many eggs are likely left — it says almost nothing about egg quality, and it cannot tell you whether you will have a baby. This article explains what the number does and does not predict, and the realistic IVF options when the ovaries respond poorly.
What AMH measures — and what it doesn’t
Anti-Müllerian hormone (AMH) is produced by the small resting follicles in the ovaries. A blood test gives a rough estimate of the size of that remaining pool — the ovarian reserve. The lower the AMH, the fewer eggs are likely to be available in any given cycle, and the fewer eggs we can usually collect during IVF.
But here is the part that gets lost. AMH is a measure of quantity, not quality. It does not tell us whether the eggs are genetically normal, and on its own it does not predict pregnancy. A woman with low AMH can still conceive, and a woman with reassuringly “normal” AMH can still struggle. The single strongest predictor of egg quality is not AMH at all — it is age. This is biology, not a reflection of effort or of anything you did wrong.
- AMH predicts: roughly how many eggs we may collect in an IVF cycle, and how to dose the stimulation medication safely.
- AMH does not predict: egg quality, the chance a given embryo is chromosomally normal, or your natural monthly chance of conceiving.
“Poor ovarian response”: POSEIDON and Bologna in plain words
When the ovaries produce only a few eggs despite proper stimulation, doctors call this poor ovarian response. Two frameworks are commonly used to describe it, and they sound more complicated than they are.
The older Bologna criteria defined a poor responder fairly bluntly — for example, someone over 40, with a low reserve test, or who had previously collected three eggs or fewer. The problem was that it lumped very different women together.
The newer POSEIDON classification is more useful because it separates women by two things that actually matter: age (under or over 35) and whether the low egg count is expected (low AMH/antral follicle count) or unexpected (normal markers but a surprisingly poor response). In plain terms, POSEIDON asks not just “how few eggs?” but “who is this happening to, and were we expecting it?” — because a 32-year-old and a 42-year-old with the same egg count have very different outlooks.
Protocol options when response is poor
There is no single “best” protocol for low reserve, and honesty matters here: no stimulation drug creates new eggs. Medication can only recruit the follicles that are already present in a given month. The aim is to collect the eggs that are there, safely and efficiently. Options a specialist may discuss include:
- Higher-dose conventional stimulation: often the first approach, though above a certain point more medication does not yield more eggs — it simply costs more and adds side effects.
- Mild stimulation: lower drug doses aiming for a smaller number of good-quality eggs, with less physical and financial burden. For some poor responders, outcomes per cycle are broadly comparable to high-dose regimens, which is why it is a reasonable choice rather than a compromise.
- DuoStim (dual stimulation): stimulating twice in the same menstrual cycle — once in the first half and again after the first egg collection. This can gather more eggs in a shorter time, which is valuable when the clock is a real factor.
- Adjuvants, graded honestly: DHEA and CoQ10 are widely used and reasonably safe, but the evidence that they improve live-birth rates is low quality — they may help, and we cannot promise they will. Growth hormone has some supportive data but remains uncertain and adds cost. Many heavily marketed “add-ons” have no good evidence at all. A good clinic will tell you which is which.
A trustworthy physician will not pretend a protocol can overcome biology. What a well-chosen protocol can do is make sure we do not waste the eggs you have. To understand how a cycle unfolds, see ovarian stimulation day by day.
Embryo banking across several cycles
When only one or two eggs come from each collection, a single cycle may not produce an embryo suitable for transfer. A common and sensible strategy is embryo (or egg) banking: doing several collections over a few months, freezing what results, and accumulating embryos before planning a transfer. This does not change the quality of any individual egg, but it improves the odds that at least one good embryo is found across the pooled attempts — a numbers game played patiently, not a magic fix. If you are weighing what to freeze and when, our comparison of egg freezing versus embryo freezing may help.
Why low AMH at 32 can be more hopeful than normal AMH at 43
This is the point that reframes everything, and it follows directly from the quantity-versus-quality distinction. Because age drives egg quality while AMH mainly reflects quantity, the two can point in opposite directions.
- A 32-year-old with low AMH may collect only a few eggs per cycle — but at her age a high proportion of those eggs are likely to be chromosomally normal. Fewer eggs, better odds per egg.
- A 43-year-old with normal AMH may collect plenty of eggs — but far fewer of them will be genetically normal, so the chance of a healthy embryo from each is lower.
Neither situation is hopeless, and neither is guaranteed. But it explains why your doctor cares as much about your age and your goals as about the AMH figure itself. Registry data collated by bodies such as the HFEA consistently show age as the dominant factor in IVF outcomes. Our article on IVF after 40 looks at the older end of this picture in more detail.
Honest framing — no false hope, no doom
A low AMH is not a diagnosis of infertility, and it is not a verdict. Many women with low reserve go on to have children, often sooner than they feared. At the same time, it would be dishonest to promise that any treatment guarantees a baby, or that supplements can turn back the clock.
At UCARER we practise own-egg and own-sperm IVF and ICSI. Egg, sperm and embryo donation are not available in Turkey, so if own-egg treatment becomes very unlikely to succeed, you deserve to hear that clearly and early rather than after repeated disappointment. That honesty is part of the care, not a failure of it. Guidance from ESHRE supports individualising treatment rather than applying one formula to everyone.
If you have a low AMH result and are unsure what it means for you, the most useful next step is a proper assessment — your age, your antral follicle count, your history and your goals together, not one number in isolation. You can read our overview of IVF treatment to understand the wider picture before you decide anything.
Sources: ESHRE, HFEA, WHO and accepted reproductive-medicine guidance. This article is for general education and does not replace a medical consultation. Reviewed by Assist. Prof. Dr. Muzaffer Uçarer (Obstetrics & Gynaecology · IVF and Reproductive Medicine), UCARER Women’s Health, Istanbul.
